Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.
LSIPR talks to Thomas Friede and Johannes Heselberger about why Germany fits this mould.
LSIPR: What are the advantages of litigating a life sciences patent in Germany?
Thomas Friede: I believe that the litigation procedure in Germany is an advantage. It is a very streamlined procedure, which is basically an exchange of written briefs—usually two rounds— before an oral hearing. The oral hearing is very condensed and focused. Even in a large case, a hearing would only be four or five hours long. If that is compared to a full trial in the US or the UK, it’s a fraction of the time and therefore it costs less.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
patent litigation, patent disputes, Germany